Tailor the management of H. pylori infection in paediatric patients to antimicrobial susceptibility profiles
- 9 Downloads
Infection with Helicobacter pylori (H. pylori) is highly prevalent worldwide, is typically acquired during childhood and, if left untreated, is the major cause of numerous complications, such as chronic gastritis and peptic ulcer disease. Management of H. pylori infection in paediatric patients differs to that of adults, and should be tailored to the antimicrobial susceptibility profile of the patient in order to achieve optimal efficacy.
Compliance with ethical standards
Conflict of interest
The article was adapted from Pediatric Drugs 2018;20(4):337–51 by employees of Adis/Springer, who are responsible for the article content and declare no conflicts of interest.
The preparation of this review was not supported by any external funding.
- 6.Koletzko S, Jones NL, Goodman KJ, et al. Evidence-based guidelines from ESPGHAN and NASPGHAN for Helicobacter pylori infection in children. J Pediatr Gastroenterol Nutr. 2011;53(2):230–43.Google Scholar
- 9.Yuan Y, Ford AC, Khan KJ, et al. Optimum duration of regimens for Helicobacter pylori eradication. Cochrane Database Syst Rev. 2013;(12):CD008337.Google Scholar
- 13.Sykora J, Valeckova K, Amlerova J, et al. Effects of a specially designed fermented milk product containing probiotic Lactobacillus casei DN-114001 and the eradication of H. pylori in children: a prospective randomized double-blind study. J Clin Gastroenterol. 2005;39(8):692–8.CrossRefGoogle Scholar